Reldesemtiv in Amyotrophic Lateral Sclerosis Results From the COURAGE-ALS Randomized Clinical Trial Key Points Question Does orally administered reldesemtiv slow disease progression in amyotrophic lateral sclerosis (ALS)? Findings A Study to Evaluate… More >>

Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort Company Expects to Initiate Enrollment of Second Dose Cohort in the First Quarter… More >>

The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital announced topline results from Regimen F of the HEALEY ALS Platform Trial evaluating fosigotifator (ABBV-CLS-7262) in people… More >>

The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital announced topline results from an analysis of Regimen G evaluating DNL343, an eIF2B agonist developed by Denali… More >>

Corcept Therapeutics, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol,… More >>

– Study failed to meet primary and secondary efficacy endpoints – PTC Therapeutics announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing… More >>

Biogen published Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study Background Hexanucleotide… More >>

uniQure, a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the Phase I/II clinical trial… More >>